Compare Imexpharm Corp. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
VND 8,254,880 Million (Small Cap)
24.00
NA
0.93%
-0.10
14.94%
3.75
Revenue and Profits:
Net Sales:
640,779 Million
(Quarterly Results - Dec 2025)
Net Profit:
107,490 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
16.92%
0%
16.92%
6 Months
1.32%
0%
1.32%
1 Year
11.13%
0%
11.13%
2 Years
81.04%
0%
81.04%
3 Years
147.53%
0%
147.53%
4 Years
55.83%
0%
55.83%
5 Years
101.8%
0%
101.8%
Imexpharm Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.89%
EBIT Growth (5y)
14.65%
EBIT to Interest (avg)
28.50
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.94
Tax Ratio
20.94%
Dividend Payout Ratio
25.88%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
20.58%
ROE (avg)
13.53%
Valuation key factors
Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
3.67
EV to EBIT
16.53
EV to EBITDA
13.47
EV to Capital Employed
3.86
EV to Sales
3.16
PEG Ratio
NA
Dividend Yield
0.99%
ROCE (Latest)
23.35%
ROE (Latest)
15.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
640,779.00
652,058.10
-1.73%
Operating Profit (PBDIT) excl Other Income
139,587.80
180,937.50
-22.85%
Interest
8,645.40
7,582.50
14.02%
Exceptional Items
0.00
0.00
Consolidate Net Profit
107,489.60
120,609.70
-10.88%
Operating Profit Margin (Excl OI)
217.80%
237.20%
-1.94%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is -1.73% vs 7.22% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -10.88% vs 66.70% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,441,085.50
2,205,119.90
10.70%
Operating Profit (PBDIT) excl Other Income
567,153.40
520,794.50
8.90%
Interest
16,501.40
3,590.40
359.60%
Exceptional Items
0.00
0.00
Consolidate Net Profit
304,389.30
297,535.70
2.30%
Operating Profit Margin (Excl OI)
189.40%
188.30%
0.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 10.70% vs 10.59% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 2.30% vs 16.85% in Dec 2024
About Imexpharm Corp. 
Imexpharm Corp.
Pharmaceuticals & Biotechnology
Imexpharm Corporation is a Vietnam-based company engaged in the pharmaceutical industry. The Company manufactures, imports, exports and trades pharmaceutical products, antiseptics, traditional medicine, medical equipment and supplies, cosmetics, supplemental food and drinks. It is also involved in the provision of packaging services and warehousing services for pharmaceutical storage purposes. In addition, the Company is involved in medicinal herb cultivation.
Company Coordinates 
Company Details
So 04, Duong 30/04, Phuong 1 , CAO LANH None : None
Registrar Details






